Key result
Percutaneous edge-to-edge mitral valve repair using a MitraClip device successfully reduced post-TAVI mitral regurgitation to mild and resolved pulmonary vascular congestion in an 86-year-old man.
Why the study?
Mitral regurgitation worsening after TAVI is associated with increased mortality, and conventional medical optimization may fail to prevent poor outcomes.
Case Report (n=1)
MitraClip may serve as an alternative treatment for patients developing worsening mitral regurgitation after TAVI when conventional medical management is insufficient.
Moderate to severe mitral regurgitation is observed in 17 to 35% of patients undergoing transcatheter aortic valve implantation. A study reporting mitral regurgitation after transcatheter aortic valve implantation due to aortic stenosis demontrated 50% of patients with moderate to severe reflux showed improvement in regurgitation, and 8.7% showed worsening of the condition, which led to increased mortality. This progression suggested conventional management, based on medication optimization, may not be able to prevent poor outcomes. We report a case on the clinical course of a patient with mitral regurgitation after transcatheter aortic valve implantation, and the use of MitraClip® as an alternative treatment and its benefits.
No takes yet. Share an insight, caveat, or question.
Schulz et al. (2023) conducted a case report in Mitral regurgitation after transcatheter aortic valve implantation (n=1). MitraClip (Percutaneous edge-to-edge mitral valve repair) was evaluated on Mitral regurgitation severity. Percutaneous edge-to-edge mitral valve repair using a MitraClip device successfully reduced post-TAVI mitral regurgitation to mild and resolved pulmonary vascular congestion in an 86-year-old man.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: